| # | Title | Journal | Year | Citations |
|---|
| 1 | 3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3) | Annals of Oncology | 2017 | 865 |
| 2 | Pooled Analysis of the Prognostic Relevance of Circulating Tumor Cells in Primary Breast Cancer | Clinical Cancer Research | 2016 | 289 |
| 3 | Sarcopenia Predicts Early Dose-Limiting Toxicities and Pharmacokinetics of Sorafenib in Patients with Hepatocellular Carcinoma | PLoS ONE | 2012 | 252 |
| 4 | Bone health in cancer: ESMO Clinical Practice Guidelines | Annals of Oncology | 2020 | 242 |
| 5 | High independent prognostic and predictive value of circulating tumor cells compared with serum tumor markers in a large prospective trial in first-line chemotherapy for metastatic breast cancer patients | Annals of Oncology | 2012 | 239 |
| 6 | Clinical application of circulating tumor cells in breast cancer: overview of the current interventional trials | Cancer and Metastasis Reviews | 2013 | 218 |
| 7 | 3rd ESO–ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3) | Breast | 2017 | 171 |
| 8 | Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients | British Journal of Cancer | 2012 | 170 |
| 9 | Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial | Annals of Oncology | 2013 | 166 |
| 10 | Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial | Annals of Oncology | 2012 | 164 |
| 11 | Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma | International Journal of Cancer | 2014 | 161 |
| 12 | Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group | European Journal of Cancer | 2017 | 134 |
| 13 | Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial | Annals of Oncology | 2013 | 126 |
| 14 | Use of platinum derivatives during pregnancy | Cancer | 2008 | 120 |
| 15 | Posterior reversible encephalopathy syndrome induced by anti-VEGF agents | Targeted Oncology | 2011 | 117 |
| 16 | Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells | Annals of Oncology | 2008 | 110 |
| 17 | Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial | Lancet Oncology, The | 2014 | 109 |
| 18 | Emerging therapeutic options for breast cancer chemotherapy during pregnancy | Annals of Oncology | 2008 | 103 |
| 19 | Everolimus as second- or third-line treatment of advanced endometrial cancer: ENDORAD, a phase II trial of GINECO | British Journal of Cancer | 2013 | 100 |
| 20 | Sorafenib exposure decreases over time in patients with hepatocellular carcinoma | Investigational New Drugs | 2012 | 95 |
| 21 | First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients | Annals of Oncology | 2011 | 92 |
| 22 | Variability of Sorafenib Toxicity and Exposure over Time: A Pharmacokinetic/Pharmacodynamic Analysis | Oncologist | 2012 | 91 |
| 23 | Lenvatinib for the Treatment of Radioiodine-Refractory Thyroid Cancer in Real-Life Practice | Thyroid | 2018 | 89 |
| 24 | High-dose intrathecal trastuzumab for leptomeningeal metastases secondary to HER-2 overexpressing breast cancer | Annals of Oncology | 2008 | 78 |
| 25 | Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience | Annals of Oncology | 2011 | 77 |
| 26 | Stromal lymphocyte infiltration after neoadjuvant chemotherapy is associated with aggressive residual disease and lower disease-free survival in HER2-positive breast cancer | Annals of Oncology | 2017 | 75 |
| 27 | Relationship between GSTP1 Ile105Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity | Annals of Oncology | 2009 | 72 |
| 28 | Assessment of circulating tumor cells and serum markers for progression-free survival prediction in metastatic breast cancer: a prospective observational study | Breast Cancer Research | 2012 | 72 |
| 29 | Predictive Value of Soluble PD-1, PD-L1, VEGFA, CD40 Ligand and CD44 for Nivolumab Therapy in Advanced Non-Small Cell Lung Cancer: A Case-Control Study | Cancers | 2020 | 72 |
| 30 | An Observational Study of Bevacizumab-Induced Hypertension as a Clinical Biomarker of Antitumor Activity | Oncologist | 2011 | 70 |
| 31 | Trastuzumab versus observation for HER2 nonamplified early breast cancer with circulating tumor cells (EORTC 90091-10093, BIG 1-12, Treat CTC): a randomized phase II trial | Annals of Oncology | 2018 | 60 |
| 32 | Sequential therapy with targeted agents in patients with advanced renal cell carcinoma: Optimizing patient benefit | Cancer Treatment Reviews | 2012 | 55 |
| 33 | Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients | European Journal of Cancer | 2017 | 54 |
| 34 | Treatment of bevacizumab-induced hypertension by amlodipine | Investigational New Drugs | 2012 | 53 |
| 35 | Final overall survival results and effect of prolonged (≥1 year) first-line bevacizumab-containing therapy for metastatic breast cancer in the ATHENA trial | Breast Cancer Research and Treatment | 2011 | 52 |
| 36 | Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid | Annals of Oncology | 2012 | 48 |
| 37 | Sorafenib in advanced melanoma: a critical role for pharmacokinetics? | British Journal of Cancer | 2012 | 44 |
| 38 | Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series | Annals of Oncology | 2013 | 43 |
| 39 | Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial | Annals of Oncology | 2013 | 42 |
| 40 | Phase II randomized study of PM01183 versus topotecan in patients with platinum-resistant/refractory advanced ovarian cancer | Annals of Oncology | 2017 | 42 |
| 41 | Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib | Medical Oncology | 2012 | 40 |
| 42 | Prognostic Value of Tumor Deposits for Disease-Free Survival in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the IDEA France Phase III Trial (PRODIGE-GERCOR) | Journal of Clinical Oncology | 2020 | 40 |
| 43 | Everolimus (RAD001): an mTOR inhibitor for the treatment of metastatic renal cell carcinoma | Expert Review of Anticancer Therapy | 2009 | 35 |
| 44 | Chemotherapy for breast cancer during pregnancy: is epirubicin safe? | Annals of Oncology | 2008 | 32 |
| 45 | Prognostic Scoring Systems for Spinal Metastases in the Era of Anti-VEGF Therapies | Spine | 2013 | 27 |
| 46 | Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant Chemotherapy | PLoS ONE | 2015 | 27 |
| 47 | FISH in chips: turning microfluidic fluorescence in situ hybridization into a quantitative and clinically reliable molecular diagnosis tool | Lab on A Chip | 2015 | 26 |
| 48 | VEGF pathway inhibition by anticancer agent sunitinib and susceptibility to atherosclerosis plaque disruption | Investigational New Drugs | 2011 | 25 |
| 49 | Hyper-alkalinization without hyper-hydration for the prevention of high-dose methotrexate acute nephrotoxicity in patients with osteosarcoma | Cancer Chemotherapy and Pharmacology | 2010 | 24 |
| 50 | Safety of bevacizumab in metastatic breast cancer patients undergoing surgery | European Journal of Cancer | 2012 | 23 |
